JPRN-UMIN000032256已完成2 期
Multi-institutional prospective randomized clinical trial to explore efficacy of postoperative exercise and oral nutritional supplement (Rehadays) in total gastrectomy for gastric cancer - Randomized clinical trial to explore efficacy of postoperative exercise and oral nutritional supplement in total gastrectomy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.diagnosis of other organ cancer 2.contraindications to Rehadays (allergy to milk or coffee) 3.active infection or inflamation 4.uncontrolled diabetes 5.pregnancy or intention for pregnancy 6.Immunodeficiency 7.clinically relevant cardiac or pulmonary disease 8.history of clinically relevant mental disorder or central nervous system disorder 9.Unsuitable patients for enrollment judged by the investigator
研究者
相似试验
招募中
2 期
Investigating breathing training for lung cancer radiotherapyLung cancerACTRN12613001177741The University of Sydney75
招募中
不适用
Prospective randomized multicenter clinical observationan of a novel cement spacer implants for for knee implant-two stage exchange after septic implant looseningT84.5Infection and inflammatory reaction due to internal joint prosthesisDRKS00004357Forschungslabor für Biomechanik und Implantattechnologie Orthopädische Klinik und Poliklinik, Universitätsmedizin Rostock100
进行中（未招募）
3 期
A clinical trial intended to compare two formulations of Trastuzumab, tablets in patients with metastatic breast cancer.CTRI/2014/05/004605Cadila Healthcare limited102
进行中（未招募）
不适用
A study Protocol for patients with relapsed osteosarcomaHigh malignancy grade of osteosarcoma relapseMedDRA version: 14.1Level: PTClassification code 10031296Term: Osteosarcoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001010-42-ITITALIAN SARCOMA GROUP
招募中
不适用
Multiinstitutional prospective interventional study of biomarkers to predict efficacy and prognosis after nivolumab in patients with previously treated advanced renal cell carcinoma.Advanced renal cell carcinoma patients who need secondary or tertiary therapyJPRN-UMIN000030400Kobe University Graduate School of Medicine200